PE-22-28

PE-22-28 is a synthetic heptapeptide (seven amino acids) developed as an optimized analog of spadin, a naturally occurring peptide derived from the propeptide of the TREK-1 potassium channel. Spadin was identified in the early 2010s as an endogenous antidepressant-like molecule, but its short duration of action (approximately 7 hours) and relatively low receptor affinity limited its therapeutic potential. PE-22-28 was engineered to address these limitations, achieving superior TREK-1 channel binding affinity, extended action duration (up to 23 hours), and improved in vivo stability.

The primary target of PE-22-28 is the TREK-1 channel (TWIK-related potassium channel 1), a two-pore-domain potassium channel expressed abundantly in neurons of the hippocampus, cortex, and other brain regions relevant to mood and cognition. TREK-1 channels regulate neuronal excitability by controlling potassium ion flow across the cell membrane. When TREK-1 is overactive, it hyperpolarizes neurons and dampens neurotransmitter release, contributing to a state associated with depressive behavior. PE-22-28 binds to and inhibits TREK-1, reversing this hyperpolarization and restoring more normal patterns of neuronal excitability and neurotransmitter signaling.

Preclinical research has generated compelling behavioral data. Mice with TREK-1 gene knockout are resistant to depressive-like states in standard models including the forced swimming test and tail suspension test. PE-22-28 and related spadin analogs replicating TREK-1 inhibition produced significant reductions in immobility time in the forced swimming test, a validated behavioral marker of antidepressant activity. Research published in a PMC peer-reviewed study confirmed that PE-22-28 displayed a better TREK-1 specificity and affinity (IC50 of 0.12 nM) compared to the parent molecule spadin (IC50 40-60 nM).

Beyond mood regulation, PE-22-28 has shown neurogenic effects. It appears to stimulate adult hippocampal neurogenesis within a few days of treatment, promoting the formation of new neurons in a brain region critical for memory encoding, pattern separation, and emotional regulation. Multiple behavioral paradigms have shown improvements in memory formation, learning ability, and recall in rodents treated with TREK-1 inhibitors, suggesting relevance to conditions beyond depression including age-related cognitive decline.